Cancer Letters
Volume 298, Issue 2 , Pages 258-263 , 8 December 2010

Non-founder BRCA1 mutations in Russian breast cancer patients

  • Aglaya G. Iyevleva

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • ,
  • Evgeny N. Suspitsin

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • ,
  • Karin Kroeze

      Affiliations

    • Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    • ,
  • Tatiana V. Gorodnova

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • ,
  • Anna P. Sokolenko

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • ,
  • Konstantin G. Buslov

      Affiliations

    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • ,
  • Dmitry A. Voskresenskiy

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • ,
  • Alexandr V. Togo

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • ,
  • Sergey P. Kovalenko

      Affiliations

    • Institute of Molecular Biology and Biophysics, Novosibirsk 630117, Russia
    • ,
  • Nienke van der Stoep

      Affiliations

    • Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    • ,
  • Peter Devilee

      Affiliations

    • Leiden University Medical Center, 2300 RC Leiden, The Netherlands
    • ,
  • Evgeny N. Imyanitov

      Affiliations

    • N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia
    • St.-Petersburg Pediatric Medical Academy, St.-Petersburg 194100, Russia
    • St.-Petersburg Medical Academy for Postgraduate Studies, St.-Petersburg 191015, Russia
    • Corresponding Author InformationCorresponding author at: N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia. Tel.: +7 812 5968951; fax: +7 812 5968947.

Received 29 March 2010 ,Revised 11 July 2010 ,Accepted 13 July 2010.

References 

  1. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer. 2007;7:937–948
  2. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11:103–105
  3. Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann. Oncol. 2007;18(Suppl. 6):vi93–vi98
  4. Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 2000;66:1963–1968
  5. Oszurek O, Gorski B, Gronwald J, Prosolow Z, Uglanica K, Murinow A, et al. Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. Clin. Genet. 2001;60:470–471
  6. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, et al. Association of two mutations in the CHEK2 gene with breast cancer. Int. J. Cancer. 2005;116:263–266
  7. Buslov KG, Iyevleva AG, Chekmariova EV, Suspitsin EN, Togo AV, Kuligina ESh, et al. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. Int. J. Cancer. 2005;114:585–589
  8. Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res. Treat. 2005;92:19–24
  9. Chekmariova EV, Sokolenko AP, Buslov KG, Iyevleva AG, Ulibina YM, Rozanov ME, et al. CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res. Treat. 2006;100:99–102
  10. Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam. Cancer. 2007;6:281–286
  11. Bogdanova N, Feshchenko S, Schürmann P, Waltes R, Wieland B, Hillemanns P, et al. Nijmegen breakage syndrome mutations and risk of breast cancer. Int. J. Cancer. 2008;122:802–806
  12. van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A, Macek M, et al. Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. Hum. Mutat. 2009;30:899–909
  13. Kwon JS, Lenehan J, Carey M, Ainsworth P. Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series. Int. J. Gynecol. Cancer. 2008;18:546–549
  14. Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, Hatae M, et al. Japanese familial ovarian cancer study group, mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin. Cancer Res. 2001;7:3144–3150
  15. Ahn SH, Son BH, Yoon KS, Noh DY, Han W, Kim SW, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett. 2007;245:90–95
  16. Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am. J. Hum. Genet. 1997;60:1239–1242
  17. Curci A, Capasso I, Romano A, Bruni P, Motti ML, Pignata S, et al. Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples. Int. J. Oncol. 2002;20:963–970
  18. Martínez-Ferrandis JI, Vega A, Chirivella I, Marín-García P, Insa A, Lluch A, et al. Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations. Hum. Mutat. 2003;22:417–418
  19. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005;294:1925–1933
  20. Meyer P, Voigtlaender T, Bartram CR, Klaes R. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany. Hum. Mutat. 2003;22:259
  21. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol. 1998;16:2417–2425
  22. Rhiem K, Flucke U, Engel C, Wappenschmidt B, Reinecke-Lüthge A, Büttner R, et al. Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast. Cancer Genet. Cytogene. 2007;176:76–79
  23. Malander S, Ridderheim M, Måsbäck A, Loman N, Kristoffersson U, Olsson H, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur. J. Cancer. 2004;40:422–428
  24. Osorio A, de la Hoya M, Rodríguez-López R, Martínez-Ramírez A, Cazorla A, Granizo JJ, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int. J. Cancer. 2002;99:305–309
  25. Dong J, Chang-Claude J, Wu Y, Schumacher V, Debatin I, Tonin P, et al. A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3’ third of the gene. Hum. Genet. 1998;103:154–161
  26. Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, et al. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int. J. Cancer. 2006;119:2832–2839
  27. De Leon Matsuda ML, Liede A, Kwan E, Mapua CA, Cutiongco EM, Tan A, et al. BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int. J. Cancer. 2002;98:596–603
  28. Vasickova P, Machackova E, Lukesova M, Damborsky J, Horky O, Pavlu H, et al. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med. Genet. 2007;8:32
  29. Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, et al. Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum. Mutat. 2004;24:534
  30. Veschi S, Aceto G, Scioletti AP, Gatta V, Palka G, Cama A, et al. High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. Ann. Oncol. 2007;18(Suppl. 6):vi86–vi92
  31. Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska M, Palomba G, et al. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol. Rep. 2008;19:263–268
  32. Ellis D, Patel Y, Yau SC, Hodgson SV, Abbs SJ. Low prevalence of BRCA1 exon rearrangements in familial and young sporadic breast cancer patients. Fam. Cancer. 2006;5:323–326
  33. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum. Genet. 2001;109:121–124
  34. Tereschenko IV, Basham VM, Ponder BA, Pharoah PD. BRCA1 and BRCA2 mutations in Russian familial breast cancer. Hum. Mutat. 2002;19:184
  35. Loginova AN, Pospekhova NI, Lyubchenko LN, Budilov AV, Zakhar’ev VM, Gar’kavtseva RF, et al. Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families. Bull. Exp. Biol. Med. 2003;136:276–278
  36. Grudinina NA, Golubkov VI, Tikhomirova OS, Brezhneva TV, Hanson KP, Vasilyev VB, et al. Prevalence of widespread BRCA1 gene mutations in patients with familial breast cancer from St. Petersburg. Russ. J. Genet. 2005;41:318–322
  37. Smirnova TY, Pospekhova NI, Lyubchenko LN, Tjulandin SA, Gar’kavtseva RF, Ginter EK, et al. High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer. Bull. Exp. Biol. Med. 2007;144:83–85
  38. E.N. Suspitsin, A.P. Sokolenko, D.A. Voskresenskiy, A.O. Ivantsov, K.V. Shelehova, V.F. Klimashevskiy, D.E. Matsko, V.F. Semiglazov, E.N. Imyanitov, Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier, Breast Cancer, in press.
  39. Neuhausen SL, Marshall CJ. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 1994;54:6069–6072
  40. Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur. J. Cancer. 2006;42:1380–1384
  41. Meric-Bernstam F. Heterogenic loss of BRCA in breast cancer: the “two-hit” hypothesis takes a hit. Ann. Surg. Oncol. 2007;14:2428–2429
  42. E. Beristain, I. Guerra, N. Vidaurrazaga, J. Burgos-Bretones, M.I. Tejada. LOH analysis should not be used as a tool to assess whether UVs of BRCA1/2 are pathogenic or not, Fam. Cancer, in press.
  43. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J. Med. Genet. 2004;41:492–507
  44. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, et al. A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet. 2007;81:873–883
  45. Gómez García EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FB, Hoogerbrugge N, et al. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res. 2009;11:R8
  46. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res. 2004;64:3790–3797
  47. Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, et al. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007;67:1494–1501
  48. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 2009;115:359–363
  49. Moiseyenko VM, Protsenko SA, Brezhnev NV, Maximov SYa, Gershveld ED, Hudyakova MA, et al. High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of 2 cases. Cancer Genet. Cytogenet. 2010;197:91–94
  50. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009;361:123–134

PII: S0304-3835(10)00361-7

doi: 10.1016/j.canlet.2010.07.013

Cancer Letters
Volume 298, Issue 2 , Pages 258-263 , 8 December 2010

Article Tools

* Image Usage & Resolution